Rapid Progression of Coronary Disease in Fabry Disease Authors: Wenqi Li, Chunting Zhao, Mingya Liu Published: 2026 ABSTRACT AbstractBackgroundMechanisms of rapidly progressive coronary disease in young Fabry patients despite standard therapy remain unclear.Case SummaryA 43-year-old man with classic Fabry disease developed exertional angina despite receiving enzyme replacement therapy and having well-controlled traditional risk factors. Coronary angiography revealed severe triple-vessel disease, and intravascular ultrasound indicated multiple vulnerable plaques. Positive autoantibodies and elevated C-reactive protein suggested an underlying inflammatory state. Management included percutaneous intervention, intensive lipid-lowering, and the addition of colchicine.DiscussionThis case suggests that Fabry disease itself may constitute a strong, independent risk factor for atherosclerosis, and secondary inflammation may further accelerate plaque progression, extending beyond the scope of traditional risk factor assessment.Take-Home MessageClinicians should be vigilant for rapid coronary progression in patients with Fabry disease. Intravascular imaging and immune evaluation can help uncover the underlying mechanisms, and comprehensive management might benefit from intensive lipid-lowering and anti-inflammatory therapy.Key words: cardiomyopathy, coronary angiography, intravascular ultrasound History of Presentation A 43-year-old man presented with recent episodes of chest pain lasting 2 to 3 minutes during brisk walking or cycling, which was relieved by rest. A bicycle exercise test was positive, leading to a diagnosis of “exertional angina” and subsequent admission to our hospital. Past Medical History In 2019, the patient underwent coronary computed tomography angiography (CTA) for atypical chest tightness, which revealed mild coronary stenosis. He was diagnosed with classic Fabry disease via genetic testing in 2021 and has been receiving regular enzyme replacement therapy with agalsidase alfa (0.2 mg/kg every 2 weeks)1 since January 2022, accompanied by periodic target organ assessments. A 2-year follow-up showed relative stability in cardiac structure and function: echocardiography indicated no significant progression of ventricular hypertrophy, left ventricular ejection fraction remained normal, and cardiac biomarkers (troponin T and N-terminal pro–B-type natriuretic peptide) were within normal limits. He has a history of smoking but has abstained for 2 years. The patient denies hypertension, diabetes, or a family history of premature coronary artery disease. To prevent atherosclerosis and reduce proteinuria, he has been on therapy with aspirin (100 mg/d), losartan (50 mg/d), and atorvastatin (20 mg/d) since 2019. Differential Diagnosis In this case, Fabry vasculopathy is certain, as supported by genetics, typical intravascular ultrasound (IVUS) findings, and rapid progression despite optimal risk factor control. Traditional risk-driven premature coronary artery disease is highly unlikely given well-managed lipids and absence of other risk factors. Vasospasm is excluded clinically by the presence of fixed stenoses and plaque rupture. The positive autoantibodies and C-reactive protein (CRP) point to possible low-grade immune activation, but without rheumatologic symptoms, a definitive vasculitis cannot be diagnosed. Hence, the accelerated phenotype most likely arises from Fabry-specific vascular pathology, with a speculative adjunctive role of nonspecific inflammatory activation. Investigations 1.Laboratory tests: Low-density lipoprotein cholesterol 1.79 mmol/L; positive antinuclear antibody at 1:320 (nuclear granular pattern) and 1:100 (cytoplasmic granular pattern); anti-Smith antibody positive; CRP level was elevated at 10.2 mg/L; normal troponin T, N-terminal pro–B-type natriuretic peptide, and blood glucose. Laboratory tests: Low-density lipoprotein cholesterol 1.79 mmol/L; positive antinuclear antibody at 1:320 (nuclear granular pattern) and 1:100 (cytoplasmic granular pattern); anti-Smith antibody positive; CRP level was elevated at 10.2 mg/L; normal troponin T, N-terminal pro–B-type natriuretic peptide, and blood glucose. 2.Imaging studies: Coronary CTA in 2025 revealed severe, diffuse triple-vessel disease, showing significant progression compared with 2019 (Figure 1). Coronary angiography confirmed diffuse stenosis in the left anterior descending (Video 1), left circumflex (Video 2), and right coronary arteries (Video 3). IVUS demonstrated multiple hypoechoic, lipid-rich plaques with plaque rupture and thrombus formation (Figure 2, Video 4, Video 5, Video 6). Imaging studies: Coronary CTA in 2025 revealed severe, diffuse triple-vessel disease, showing significant progression compared with 2019 (Figure 1). Coronary angiography confirmed diffuse stenosis in the left anterior descending (Video 1), left circumflex (Video 2), and right coronary arteries (Video 3). IVUS demonstrated multiple hypoechoic, lipid-rich plaques with plaque rupture and thrombus formation (Figure 2, Video 4, Video 5, Video 6). Comparison of Coronary Computed Tomography Angiography Between 2019 and 2025, with Arrows Indicating the Stenosis LAD = left anterior descending artery; LCX = left circumflex artery; RCA = right coronary artery. Coronary Angiography and IVUS Images in 2025 The intravascular ultrasound (IVUS) images correspond to the stenotic segments of the relevant vessels (white arrows). IVUS demonstrates plaque rupture (red arrows), with visible disruption and false lumen formation; lipid-rich plaque (blue arrows), characterized by a markedly attenuated hypoechoic zone without overlying hyperechoic calcification; and signs of thrombus formation (yellow dashed circles), appearing as a mixed-echoic mass within the lumen. Abbreviations as in Figure 1. Management 1.Interventional therapy: Percutaneous coronary stent implantation was performed in the right coronary artery and left anterior descending; drug-coated balloon angioplasty was performed in the left circumflex and its diagonal branch. Interventional therapy: Percutaneous coronary stent implantation was performed in the right coronary artery and left anterior descending; drug-coated balloon angioplasty was performed in the left circumflex and its diagonal branch. 2.Intensified medical therapy: 1) dual antiplatelet therapy: aspirin 100 mg daily and clopidogrel 75 mg daily; 2) intensive lipid-lowering: atorvastatin 20 mg daily, ezetimibe 10 mg daily, and evolocumab 140 mg every 2 weeks; 3) anti-inflammatory therapy: colchicine 0.5 mg daily; 4) continued regular enzyme replacement therapy (ERT) and renin-angiotensin system blockade (losartan). Intensified medical therapy: 1) dual antiplatelet therapy: aspirin 100 mg daily and clopidogrel 75 mg daily; 2) intensive lipid-lowering: atorvastatin 20 mg daily, ezetimibe 10 mg daily, and evolocumab 140 mg every 2 weeks; 3) anti-inflammatory therapy: colchicine 0.5 mg daily; 4) continued regular enzyme replacement therapy (ERT) and renin-angiotensin system blockade (losartan). Outcome and Follow-Up Successful revascularization was achieved, and the patient's chest pain resolved. He continues the comprehensive treatment regimen post discharge, with planned regular follow-up for coronary imaging, lipid profile, and immune markers. Discussion The severity, diffuseness, and activity (as indicated by IVUS showing multiple soft plaque ruptures) of this patient's coronary disease far exceeded the burden expected from his traditional risk factors. The root cause lies in the inherent vascular pathology of Fabry disease1—the alpha-galactosidase A gene mutation leads to persistent glycosphingolipid deposition within the vessel wall, directly injuring the endothelium and triggering inflammation, thereby creating a highly pro-atherogenic environment. Previous literature confirms that coronary plaques in patients with Fabry disease have higher lipid content, greater instability, and significant sphingolipid deposition within the vessel wall, which aligns closely with the IVUS findings in this case.2 The patient's serological findings revealed positive antinuclear antibody with nuclear granular and cytoplasmic granular patterns, along with anti-Smith antibody positivity and an elevated CRP, indicating an ongoing systemic inflammatory state.3 Despite these serological abnormalities, the patient had no clinical features suggestive of a definitive connective tissue disease (eg, no rash, arthritis, serositis, nephritis, or neurological manifestations); therefore, a formal diagnosis of systemic lupus erythematosus or mixed connective tissue disease cannot be established. Whether such inflammatory activation directly accelerates coronary plaque progression or merely represents an epiphenomenon secondary to Fabry-related tissue damage remains uncertain. Nonetheless, it is plausible that this inflammatory milieu—on a background of Fabry vasculopathy—may have contributed to the unusually rapid progression of coronary atherosclerosis observed in this case. Further studies with larger cohorts and longitudinal follow-up are needed to clarify the causal relationship between autoantibodies, systemic inflammation, and coronary outcomes in Fabry disease. The addition of colchicine in this patient, supported by objective evidence of systemic inflammation (elevated CRP and autoantibody positivity) and vulnerable plaques on IVUS, is in line with current guideline recommendations for anti-inflammatory therapy in patients with established coronary artery disease.4,5 While long-term ERT has been shown to stabilize renal function and cardiac structure in patients with Fabry disease, evidence from large cohorts indicates that up to 36% of patients still experience left ventricular mass progression, and essential glycosphingolipid deposits are never completely cleared from the myocardium even after decades of treatment.6 In the specific context of coronary artery disease, the protective effect of ERT against rapidly progressive atherosclerosis is less well established. In our patient, the presence of chronic inflammation together with incomplete clearance of vascular globotriaosylceramide and potential mannose-6-phosphate receptor downregulation might have limited ERT efficacy, contributing to the accelerated coronary phenotype despite regular and adequate ERT. These observations suggest that current ERT regimens may offer only incomplete vascular protection in patients with advanced or rapidly progressive coronary involvement, underscoring the need for adjunctive risk factor control, anti-inflammatory therapy, and early initiation of treatment before irreversible organ damage occurs. This highlights that patients with Fabry disease should be considered at very high risk for coronary artery disease, warranting early and proactive cardiovascular assessment (eg, coronary CTA/angiography, IVUS for plaque characterization). Therapeutically, beyond strict risk factor control and ERT, targeting inflammatory pathways (eg, with colchicine) has become an important area of exploration. Conclusions Fabry disease may be an independent risk factor for rapidly progressive coronary artery disease, and inflammatory activation might be involved. Clinical management should integrate advanced imaging, intensive lipid-lowering, and individualized anti-inflammatory strategies. Funding Support and Author Disclosures This work was supported by grants from the Sanming Project of Medicine in Shenzhen, China (No. SZSM202411021), the Sanming Project of Medicine in Shenzhen (No. SZSM202311022), and Shenzhen Clinical Research Center for Rare Diseases (LCYSSQ20220823091402005). The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Take-Home Message •Fabry disease can drive “nontraditional” rapid atherosclerosis. Identifying and intervening in its unique vascular inflammatory and immune components are key to improving prognosis. Fabry disease can drive “nontraditional” rapid atherosclerosis. Identifying and intervening in its unique vascular inflammatory and immune components are key to improving prognosis. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper.Visual SummaryTimeline of the CaseTimelineEvents6 y before percutaneous coronary intervention (PCI)Presented with chest tightness and coronary computed tomography angiography (CTA) indicated mild disease, atorvastatin 20 mg daily was initiated.4 y before PCIDiagnosed with Fabry disease.3 y before PCIInitiated regular and adequate enzyme replacement therapy.1 mo before PCIExercise electrocardiogram turned positive, typical chest pain symptoms emerged.1 wk before PCICoronary CTA showed rapid progression with low-density lipoprotein cholesterol controlled at 1.79 mmol/L.PCI dayAngiography showed severe stenosis, intravascular ultrasound confirmed vulnerable plaques, and PCI was performed for revascularization. Given the positivity of multiple autoantibodies and elevated CRP, intensive lipid-lowering therapy and colchicine were initiated.Post dischargeSymptoms resolved, under comprehensive treatment follow-up. Visual SummaryTimeline of the CaseTimelineEvents6 y before percutaneous coronary intervention (PCI)Presented with chest tightness and coronary computed tomography angiography (CTA) indicated mild disease, atorvastatin 20 mg daily was initiated.4 y before PCIDiagnosed with Fabry disease.3 y before PCIInitiated regular and adequate enzyme replacement therapy.1 mo before PCIExercise electrocardiogram turned positive, typical chest pain symptoms emerged.1 wk before PCICoronary CTA showed rapid progression with low-density lipoprotein cholesterol controlled at 1.79 mmol/L.PCI dayAngiography showed severe stenosis, intravascular ultrasound confirmed vulnerable plaques, and PCI was performed for revascularization. Given the positivity of multiple autoantibodies and elevated CRP, intensive lipid-lowering therapy and colchicine were initiated.Post dischargeSymptoms resolved, under comprehensive treatment follow-up. Timeline of the Case Appendix Video 1 LAD Angiogram Video 2 LCX Angiogram Video 3 RCA Angiogram Video 4 LAD IVUS Image Video 5 LCX IVUS Image Video 6 RCA IVUS Image References Associated Data Supplementary Materials Video 1 LAD Angiogram Video 2 LCX Angiogram Video 3 RCA Angiogram Video 4 LAD IVUS Image Video 5 LCX IVUS Image Video 6 RCA IVUS Image